Inventor · disambiguated record
Andrew John Eatherton
Also filed as: EATHERTON ANDREW J · EATHERTON ANDREW JOHN
8 granted patents·16 pending applications·13 citations·filing 2003–2023
80Inventor score
Files withASTRAZENECA AB9EATHERTON ANDREW JOHN5GLAXO GROUP LTD5EATHERTON ANDREW J3ANDREOTTI DANIELE1
Top patents by PatentIndex Score
24 records- 0185US10457679B2Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancerASTRAZENECA AB·Filed 2017·Granted Oct 29, 2019·3 cites·20 claims
- 0281US2023286981A1Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating CancerASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 0378US10882858B2Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancerASTRAZENECA AB·Filed 2019·Granted Jan 5, 2021·0 cites·4 claims
- 0474US11613539B2Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancerASTRAZENECA AB·Filed 2020·Granted Mar 28, 2023·0 cites·9 claims
- 0574US8778939B2CompoundsNICHOLS PAULA LOUISE·Filed 2010·Granted Jul 15, 2014·7 cites·13 claims
- 0665US7589206B2Pyrrolopyridine derivativesGLAXO GROUP LTD·Filed 2005·Granted Sep 15, 2009·1 cites·13 claims
- 0763US9365551B22-(benzyloxy) benzamides as LRRK2 kinase inhibitorsANDREOTTI DANIELE·Filed 2011·Granted Jun 14, 2016·1 cites·14 claims
- 0860US7635701B2Pyrimidine derivatives and their use as CB2 modulatorsGLAXO GROUP LTD·Filed 2003·Granted Dec 22, 2009·1 cites·19 claims
- 0960US2022127281A1Heteroaryl compounds that inhibit g12c mutant ras proteinsASTRAZENECA AB·Filed 2021·Application pending·0 cites
- 1057US11407765B2Tetracyclic heteroaryl compoundsASTRAZENECA AB·Filed 2019·Granted Aug 9, 2022·0 cites·19 claims
- 1154US2010041654A1Pyrimidine Derivatives And Their Use As CB2 ModulatorsEATHERTON ANDREW JOHN·Filed 2009·Application pending·0 cites
- 1247US2010056527A1Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptorGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 1345US2020109153A1Heteroaryl compounds that inhibit g12c mutant ras proteinsASTRAZENECA AB·Filed 2018·Application pending·0 cites
- 1444US2018318287A1Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating CancerASTRAZENECA AB·Filed 2016·Application pending·0 cites
- 1544US2009018128A1CompoundsEATHERTON ANDREW JOHN·Filed 2007·Application pending·0 cites
- 1644US2018280377A1Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating CancerASTRAZENECA AB·Filed 2016·Application pending·0 cites
- 1743US2008221097A1Imidazopyridine Derivatives as Cannabinoid Receptor LigandsGLAXO GROUP LTD·Filed 2006·Application pending·0 cites
- 1841US2008261977A1Pyrimidine Derivatives as Cannabinoid Receptor ModulatorsEATHERTON ANDREW JOHN·Filed 2005·Application pending·0 cites
- 1941US2008280868A1Pyridine Derivatives and Their Use as Cb2 Receptor ModulatorsEATHERTON ANDREW JOHN·Filed 2005·Application pending·0 cites
- 2039US2009264452A12-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory DisordersEATHERTON ANDREW JOHN·Filed 2005·Application pending·0 cites
- 2138US2006247261A1Pyrimidine compoundsEATHERTON ANDREW J·Filed 2003·Application pending·0 cites
- 2236US2007129367A1Pyridine derivatives as cb2 receptor modulatorsEATHERTON ANDREW J·Filed 2003·Application pending·0 cites
- 2336US2006240048A1Pyridine derivatives as cb2 receptor modulatorsEATHERTON ANDREW J·Filed 2003·Application pending·0 cites
- 2434US2008132505A1Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In MedicineGLAXO GROUP LTD·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Andrew John Eatherton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →